<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04797377</url>
  </required_header>
  <id_info>
    <org_study_id>022019</org_study_id>
    <nct_id>NCT04797377</nct_id>
  </id_info>
  <brief_title>Autologous Intraovarian Platelet Rich Plasma Treatment in Women With Poor Ovarian Response</brief_title>
  <official_title>Effects of Autologous Intraovarian Platelet Rich Plasma in Women With Poor Ovarian Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nadezhda Women's Health Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nadezhda Women's Health Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reproductive age women diagnosed with poor ovarian response (POR) based on Bologna criteria&#xD;
      with a history of at least two prior failed ICSI cycle will be recruited for the study.&#xD;
      Antral follicle count (AFC), serum anti-mullerian hormone (AMH), and early follicular phase&#xD;
      serum follicle stimulating hormone (FSH) levels will determined at baseline. Autologous blood&#xD;
      obtained from peripheral vein will be used to prepare PRP following standard protocols and&#xD;
      will be injected to both ovaries. Ovarian reserve parameters and ICSI outcomes will be&#xD;
      determined.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Reproductive age women diagnosed with POR based on Bologna criteria with a history of at&#xD;
      least two prior failed intracytoplasmic sperm injection (ICSI) cycle will recruited for the&#xD;
      study. Antral follicle count (AFC), serum anti-mullerian hormone (AMH), and early follicular&#xD;
      phase serum follicle stimulating hormone (FSH) levels will be determined at baseline.&#xD;
      Autologous blood obtained from peripheral vein will be used to prepare PRP following standard&#xD;
      protocols. PRP injection will be performed under sedation anesthesia, using a 11.8 inch (30&#xD;
      cm) single lumen 21G needles under transvaginal ultrasound guidance. On the 2 to 4th days of&#xD;
      the first three menstrual cycles following the procedure, AFC, AMH, and FSH levels will be&#xD;
      re-assessed. Patients with at least one antral follicle will be started on ovarian&#xD;
      stimulation for ICSI, followed by embryo transfer. Biomarkers of ovarian reserve (AFC, FSH,&#xD;
      AMH), and ICSI outcome parameters (number of metaphase II (MII) oocytes, blastocyst embryos,&#xD;
      fertilization rate, oocyte and embryo quality) will be followed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 8, 2021</start_date>
  <completion_date type="Anticipated">September 4, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 4, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>After the women are recruited for the study, Antral follicle count (AFC), serum anti-mullerian hormone (AMH) and follicle stimulating hormone (FSH) levels will be determined at baseline and will be repeated beginning with the first menstrual cycle after treatment. Approximately 22 ml of blood sample will be collected under sterile conditions, and PRP will be prepared. The same day, within 1 hour of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into both ovaries. Ovarian reserve (AFC, FSH, AMH), and ICSI outcome parameters (number of MII oocytes, fertilization rate, oocyte and embryo quality) will be followed up to three months after the intervention.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oocyte number</measure>
    <time_frame>3 months</time_frame>
    <description>Number of Metaphase II oocyte yield.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oocyte quality</measure>
    <time_frame>3 months</time_frame>
    <description>Oocytes will be classified based on morphological assessment and enumeration of extracytoplasmic anomalies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Embryo number</measure>
    <time_frame>3 months</time_frame>
    <description>Number of produced embryos per cycle.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Embryo quality</measure>
    <time_frame>3 months</time_frame>
    <description>Morphological evaluation of the cultured embryos will be conducted 120 or 144 hr following sperm injection. Blastocysts scoring will be performed on day 5 or 6 depending on the blastocoel cavity expansion and on the inner cell mass and trophectoderm cells integrity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fertilization rate</measure>
    <time_frame>3 months</time_frame>
    <description>Fertilization rate will be calculated as the percentage of transformation of the injected oocytes into two pronuclei.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antral follicle count (AFC)</measure>
    <time_frame>3 months</time_frame>
    <description>Number of Antral Follicles determined by pelvic sonogram on day 2 or 3 of the cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum anti-mullerian hormone (AMH)</measure>
    <time_frame>3 months</time_frame>
    <description>Serum concentration of anti-mullerian hormone determined on day 3 of the cycle by an electrochemiluminescent (ECLIA) immunoanalyzer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum follicle stimulating hormone (FSH)</measure>
    <time_frame>3 months</time_frame>
    <description>Serum concentration of follicle stimulating hormone (FSH) levels determined on day 3 of the cycle by an electrochemiluminescent (ECLIA) immunoanalyzer.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Poor Ovarian Reserve</condition>
  <arm_group>
    <arm_group_label>Ovarian Reserve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with diminished ovarian reserve or premature ovarian insufficiency</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous ovarian PRP injection</intervention_name>
    <description>The same day, within 1 hour of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into both ovaries using 11.8 inch (30 cm) single lumen 21G needles. The ovaries will be reached using needle guide preventing vascular or other structures rupture. The needle will be advanced into the centre of the ovarian medula without rotation. The correct tip placement will be confirmed by ultrasound. The activated PRP will be slowly introduced during careful retraction of the needle across the previously traversed ovarian cortex. The final PRP volume will be deposited under the ovarian capsule and the needle exit the ovary. Approximately 0.5 ml of the PRP solution will be injected into each ovary. After the procedure, the patients will be taken to the recovery room and will be observed for 30 minutes and also be discharged home on the same day.</description>
    <arm_group_label>Ovarian Reserve</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with POR based on Bologna criteria and with a history of at least&#xD;
             two prior failed ICSI cycles&#xD;
&#xD;
          -  A previous assisted reproductive technology cycle with less than 3 oocytes&#xD;
             (conventional stimulation protocol) and AFC &lt; 7&#xD;
&#xD;
          -  The same ovarian stimulation protocol before and after the PRP treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age over 46 years,&#xD;
&#xD;
          -  Body mass index (BMI) â‰¥ 30 kg/m2,&#xD;
&#xD;
          -  Presence of pregnancy&#xD;
&#xD;
          -  Uncontrolled endocrine disorders (polycystic ovary syndrome and others)&#xD;
&#xD;
          -  Parental genetic and chromosomal disorders,&#xD;
&#xD;
          -  Immunological disorders&#xD;
&#xD;
          -  Cancer diagnostics&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Based on gender identity</gender_description>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>46 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dimitar Parvanov, PhD</last_name>
    <phone>+359885944618</phone>
    <email>dimparvanov@abv.bg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nadezhda Women's Health Hospital</name>
      <address>
        <city>Sofia</city>
        <zip>1373</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitar Parvanov, PhD</last_name>
      <phone>+359885944618</phone>
      <email>dimparvanov@abv.bg</email>
    </contact>
    <contact_backup>
      <last_name>Rumiana Ganeva, MSc</last_name>
      <phone>+359898484825</phone>
      <email>rum.ganeva@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <reference>
    <citation>Drakopoulos P, Bardhi E, Boudry L, Vaiarelli A, Makrigiannakis A, Esteves SC, Tournaye H, Blockeel C. Update on the management of poor ovarian response in IVF: the shift from Bologna criteria to the Poseidon concept. Ther Adv Reprod Health. 2020 Jul 31;14:2633494120941480. doi: 10.1177/2633494120941480. eCollection 2020 Jan-Dec. Review.</citation>
    <PMID>32844159</PMID>
  </reference>
  <reference>
    <citation>Zhang Y, Zhang C, Shu J, Guo J, Chang HM, Leung PCK, Sheng JZ, Huang H. Adjuvant treatment strategies in ovarian stimulation for poor responders undergoing IVF: a systematic review and network meta-analysis. Hum Reprod Update. 2020 Feb 28;26(2):247-263. doi: 10.1093/humupd/dmz046.</citation>
    <PMID>32045470</PMID>
  </reference>
  <reference>
    <citation>Panda SR, Sachan S, Hota S. A Systematic Review Evaluating the Efficacy of Intra-Ovarian Infusion of Autologous Platelet-Rich Plasma in Patients With Poor Ovarian Reserve or Ovarian Insufficiency. Cureus. 2020 Dec 12;12(12):e12037. doi: 10.7759/cureus.12037. Review.</citation>
    <PMID>33457137</PMID>
  </reference>
  <reference>
    <citation>Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020. Int J Mol Sci. 2020 Oct 21;21(20). pii: E7794. doi: 10.3390/ijms21207794. Review.</citation>
    <PMID>33096812</PMID>
  </reference>
  <reference>
    <citation>Sills ES, Wood SH. Autologous activated platelet-rich plasma injection into adult human ovary tissue: molecular mechanism, analysis, and discussion of reproductive response. Biosci Rep. 2019 Jun 4;39(6). pii: BSR20190805. doi: 10.1042/BSR20190805. Print 2019 Jun 28. Review.</citation>
    <PMID>31092698</PMID>
  </reference>
  <reference>
    <citation>Bos-Mikich A, de Oliveira R, Frantz N. Platelet-rich plasma therapy and reproductive medicine. J Assist Reprod Genet. 2018 May;35(5):753-756. doi: 10.1007/s10815-018-1159-8. Epub 2018 Mar 21.</citation>
    <PMID>29564738</PMID>
  </reference>
  <reference>
    <citation>Alves R, Grimalt R. A Review of Platelet-Rich Plasma: History, Biology, Mechanism of Action, and Classification. Skin Appendage Disord. 2018 Jan;4(1):18-24. doi: 10.1159/000477353. Epub 2017 Jul 6. Review.</citation>
    <PMID>29457008</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Platelet-Rich Plasma</keyword>
  <keyword>Poor Ovarian Reserve</keyword>
  <keyword>Oocyte Quality</keyword>
  <keyword>Embryo Quality</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

